Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care

Annals of Medicine

Volumn 42, Issue 1, 2010, Pages 19-35

  Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antiplatelets; Antithrombotics; Atherothrombosis; Ischemic stroke; Myocardial ischemia; Peripheral artery disease; Residual risk; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; ATORVASTATIN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DARAPLADIB; DU 176B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PLACEBO; PRASUGREL; PRAVASTATIN; RIVAROXABAN; ROSUVASTATIN; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; WARFARIN; YM 150;

ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COST OF ILLNESS; GASTROINTESTINAL HEMORRHAGE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; ISCHEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOGENESIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ATHEROSCLEROSIS; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MYOCARDIAL INFARCTION; PATIENT CARE; RECURRENCE; STROKE; THROMBOSIS;

EID: 75149155661     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890903260898     Document Type: Review

References (138)

1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348: 1329-1339.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvas-tatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
4. Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL. AHA Science Advisory: Lyon Diet Heart Study. Benefi ts of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation. 2001; 103: 1823-1825.
5. Lee KW, Lip G Y. Effects of lifestyle on hemostasis, fi bri-nolysis, and platelet reactivity: a systematic review. Arch Intern Med. 2003; 163: 2368-2392.
6. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modifi cation and pharmacotherapy for obesity. N Engl J Med. 2005; 353: 2111-2120.
7. Ferguson JJ. The role of oral antiplatelet agents in athero-thrombotic disease. Am J Cardiovasc Drugs. 2006; 6: 149-157.
8. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117: e25-146.
9. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affi rms the value of this guideline. Circulation. 2006; 113: e409-49.
10. Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, et al. Ethnic-specifi c prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007; 32: 328-333.
11. Selvin E, Erlinger T P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004; 110: 738-743.
12. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992; 326: 381-386.
13. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associa tion for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interven tions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006; 113: e463-654.
14. Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg. 1989; 9: 691-6; discussion 6-7.
15. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991; 87: 119-128.
16. McDermott MM, Feinglass J, Slavensky R, Pearce WH. The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease. J Gen Intern Med. 1994; 9: 445-449.
17. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfraction-ated heparin and warfarin: current and future advances. Circulation. 2007; 116: 552-560.
18. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996; 25: 1172-1181. (Pubitemid 27013522)
19. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004; 292: 453-461.
20. Wasserman EJ, Shipley NM. Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability. Mt Sinai J Med. 2006; 73: 431-439.
21. Libby P, Theroux P. Pathophysiology of coronary arter y disease. Circulation. 2005; 111: 3481-3488.
22. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997; 100: 2680-2690.
23. Napoli C, de Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, et al. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-defi cient mice and alters aortic gene expression determined by microarray. Circulation. 2002; 105: 1360-1367.
24. Napoli C, Witztum JL, de Nigris F, Palumbo G, D'Armiento FP, Palinski W. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation. 1999; 99: 2003-2010.
25. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007; 357: 2482-2494.
26. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classifi cation scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262-1275
27. Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol. 1986; 63: 681-691.
28. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008; 28: 403-412.
29. Brass LF. Thrombin and platelet activation. Chest. 2003; 124: Suppl: 18-25S.
30. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, et al. A revised model of platelet aggregation. J Clin Invest. 2000; 105: 783-791.
31. Gawaz M, Langer H, May AE. Platelets in infl ammation and atherogenesis. J Clin Invest. 2005; 115: 3378-3384.
32. May AE, Seizer P, Gawaz M. Platelets: infl ammatory fi re-bugs of vascular walls. Arterioscler Thromb Vasc Biol. 2008; 28: s5-10.
33. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002; 100: 917-924
34. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol. 2005; 83: 196-198.
35. Satoh M, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M. Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Front Biosci. 2008; 13: 6708-6715.
36. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifi able risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952 (Pubitemid 39208455)
37. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389
38. Prevention of cardiovascular events and death with pravas-tatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339: 1349-1357.
39. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549-559.
40. Cannon CP, Braunwald E, Mc Cabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504.
41. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative sim-vastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292: 1307-1316.
42. Gissi HFI, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 1231-1239.
43. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357: 2248-2261. (Pubitemid 350190755)
44. La Rosa JC, Grundy SM, Waters D D, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-1435.
45. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myo-cardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294: 2437-2445.
46. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto A, Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-2207.
47. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335: 1001-1009.
48. Waters D D, La Rosa JC, Barter P, Fruchart JC, Gotto A Jr, Carter R, et al. Effects of high-dose atorvastatin on cerebrov-ascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006; 48: 1793-1799. (Pubitemid 44648630)
49. Levy WC. Observational studies of statins in systolic heart failure. Heart Fail Clin. 2008; 4: 201-208.
50. Stypmann J, Schubert A, Welp H, Schulte H, Assmann G, Breithardt G, et al. Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol. 2008; 31: 478-481
51. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail. 2008; 14: 140-144.
52. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braun-wald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006; 48: 438-445.
53. O'Regan C, W u P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008; 121: 24-33.
54. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007 (4): CD000123.
55. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992; 340: 1173-1178.
56. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001; 87: 1058-1063.
57. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ram-ipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145-153.
58. Fox KM. Effi cacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362: 782-788.
59. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibi tion in stable coronary artery disease. N Engl J Med. 2004; 351: 2058-2068.
60. Saha SA, Molnar J, Arora RR. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials. J Cardio-vasc Pharmacol Ther. 2007; 12: 192-204.
61. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372: 1174-1183.
62. Yusuf S, Te o KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-1559.
63. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008; 359: 1225-1237.
64. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-1041.
65. Smith S, Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363-2372
66. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589.
67. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008; 359: 1565-1576.
68. Patel A, Mac Mahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.
69. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
70. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366: 1622-1632.
71. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008; 372: 1962-1976.
72. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008; 52: 1482-1489.
73. Campbell DJ, Aggarwal A, Esler M, Kaye D. beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 2001; 358: 1609-1610.
74. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007; 50: e1-157
75. Randomised double-blind trial of fi xed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet. 1997; 350: 389-396.
76. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002; 105: 557-563.
77. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001; 345: 1444-1451.
78. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357: 217-227
79. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol. 1997; 42: 857-865.
80. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefi t. Ann Intern Med. 2005; 143: 241-250.
81. Turpie AG. New oral anticoagulants in atrial fi brillation. Eur Heart J. 2008; 29: 155-165.
82. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001; 52: 563-571.
83. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-1717.
84. Bhatt DL, Flather M D, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-1988
85. Persantine Aspirin Trial in cerebral ischemia. Part II: End-point results. The American-Canadian Co-Operative Study group. Stroke. 1985; 16: 406-415
86. The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet. 1987; 2: 1351-1354.
87. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al. 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983; 14: 5-14. (Pubitemid 13174990)
88. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipy-ridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143: 1-13.
89. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006; 367: 1665-1673.
90. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton W A, et al. Aspirin and extended-release dipyrida-mole versus clopidogrel for recurrent stroke. N Engl J Med. 2008; 359: 1238-1251.
91. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fi brillation. N Engl J Med. 2009; 360: 2066-2078.
92. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuiv-enhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007; 356: 1620-1630.
93. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356: 1304-1316.
94. Tardif JC, Gregoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004; 110: 3372-3377.
95. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358: 1431-1443.
96. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dys-lipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007; 370: 1907-1914.
97. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004; 110: 3512-3517.
98. Crouse J, 3rd, Raichlen JS, Riley W A, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007; 297: 1344-1353.
99. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001; 357: 577-581
100. Barter PJ, Caulfi eld M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357: 2109-2122
101. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008; 336: 195-198
102. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49: 1505-1516.
103. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373: 309-317.
104. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-362.
105. Simon T, Ver stuyft C, Mar y-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360: 363-375
106. Jer nberg T, Payne C D, Winter s KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006; 27: 1166-1173.
107. Brown TM, Bittner V. Biomarkers of atherosclerosis: clinical applications. Curr Cardiol Rep. 2008; 10: 497-504.
108. Catella F, Healy D, Lawson JA, Fitz Gerald GA. 11-Dehy-drothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA. 1986; 83: 5861-5865.
109. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002; 105: 1650-1655.
110. Budoff MJ, Gul KM. Expert review on coronary calcium. Vasc Health Risk Manag. 2008; 4: 315-324.
111. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratifi cation in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006; 27: 713-721.
112. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcifi cation, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005; 46: 158-165.
113. Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol. 2003; 92: 827-829.
114. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003; 228: 826-833.
115. Vliegenthart R, Oudkerk M, Song B, van der Kuip DA, Hofman A, Witteman JC. Coronary calcifi cation detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcifi cation Study. Eur Heart J. 2002; 23: 1596-1603.
116. Georgiou D, Budoff MJ, Kaufer E, Kennedy JM, Lu B, Brundage BH. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol. 2001; 38: 105-110.
117. Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA, et al. Long-term prognostic value of coronary calcifi cation detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 2001; 104: 412-417.
118. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisen-berg MJ, Grundy SM, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000125 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007; 115: 402-426.
119. Laurent S, Boutouyrie P. Ar terial stiffness: a new surrogate end point for cardiovascular disease?. J Nephrol. 2007; 20: (Suppl 12): S45-50.
120. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999; 99: 2434-2439.
121. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation. 2002; 106: 2085-2090.
122. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 1236-1241.
123. Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003; 34: 1203-1206
124. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006; 113: 657-663. (Pubitemid 43754329)
125. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005; 111: 3384-3390.
126. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmus-sen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006; 113: 664-670.
127. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001; 103: 987-992.
128. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hyper-tens. 2008; 21: 500-508.
129. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003; 115: 41-46.
130. Libby P, Ridker PM, Maseri A. Infl ammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
131. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Sti-jnen T, Breteler MM, et al. Lipoprotein-associated phos-pholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005; 111: 570-575.
132. Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet. 2009; 373: 649-658.
133. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Ver-heye S, Aschermann M, et al. Effects of the direct lipopro-tein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008; 118: 1172-1182.
134. The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). NCT00799903. Available at: http://www.clinicaltrials. gov/ct2/show/NCT007 99903 (accessed 26 February 2009).
135. FRANCIS-ACS Trial: A Study of the Safety and Effi cacy of A 002 in Subjects With Acute Coronary Syndromes. NCT00743925. Available at: //www.clinicaltrials.gov/ct2/show/NCT00743925 (accessed 26 February 2009).
136. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an infl ammatory hypothesis toward consensus. J Am Coll Cardiol. 2007; 49: 2129-2138.
137. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon R, 3rd, Criqui M, et al. Markers of infl ammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499-511.
138. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Sr Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197-1206.